NASDAQ · CRMD
CorMedix Inc.
Healthcare · Biotechnology
$5.70▼ 25.46% ($1.95)at close
After hours$5.74▲ 0.87%7:58 PM ET
Market cap
$443.89M
P/E
2.81
EPS (TTM)
$2.02
Valuation
Revenue & margin DCF
Verdict: cheap. Price below all scenarios.
The price holds with revenue shrinking 4.3% a year for 10 years. Our scenarios assume 14.1–24.4%.
That's below its past 4-year pace of 535.6%.
Value per share
Base case
$295.85
Price used $5.70 is 98% below this
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
1 more note
This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.
Revenue each value needs
Revenue today $462M. The price needs $297M by 2036. Base case: $2.8B. At its recent pace: $49,777.1T. Bear to Bull: $1.7B to $4.1B.
Revenue today $462M. The price needs $297M by 2036. Base case: $2.8B. At its recent pace: $49,777.1T. Bear to Bull: $1.7B to $4.1B.
Revenue in 2036
today $462M
−$2.5Bless than the Base case
Value per share · Base case
$295.85
Price $5.70
98% below this
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 30.0%
- Discount rate
- 9.2%
Only 4 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
1 more note
This estimate is at least 3× the price used. Review the growth, margin and investment assumptions behind the gap.
USD · TTM ending Jun 30, 2026 · Price Oct 30, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 50.95% over the last year. Revenue grew 280.5% over the trailing twelve months. Operating margin moved from 40.6% to 46.95%. Free cash flow grew 727.72% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently 46.95%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Return analysis
Company profile
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally.
Market multiples
Stock splits
Every 5 shares became 1
Profitability & growth
Analyst consensus
8
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 11, 2026
Q3 FY26 · EPS est -$0.09 · Revenue est $52.9M
Same quarter, year over year
FY26 YTD +24.1%Each cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $0.72 vs $0.58 · all 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- $1.33
- n/m
- FY24
- -$0.33
- —
n/m: last year’s figure was zero, a loss or too small to compare against
Q2 FY26
Reported Aug 13, 2026 · Latest
HoverTap a cell to inspect
Actual
$0.29
Estimate
$0.24
Year over year
+3.6%
Vs prior quarter
-32.6%
Institutional Sentiment
CorMedix Inc. · CRMD
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.